Egene Inc (fka EGEI)

[smart stock guy]

Hey has any one looked at DHSM ??? I've been buying for about a month slow but steady mover..

[itsmikie]

has anyone gotten the new shares yet???

[Horror_ Fn]

Still waiting for it to go up some more as the highs get higher! So I'm on hold with probable sell before the merger in mind...

The buy flag is still waiving for Egene and I just called the company to confirm that my new QGEN price will be at 16.57, which is over 1.50 lower than the current trade price of QGEN.

Anyone who sold early, could be regretting it!

Comments?

[Horror_ Fn]

This could be a good time. American Bulls says BUY!:

http://americanbulls.com/StockPage.asp?CompanyTicker=EGEI&MarketTicker=OTC&TYP=S

Egene is a BUY!

Egene! Ready to save the world!

[Horror_ Fn]

Good luck to you, as well!

[cojin]

I've decided to sell. I'll keep monitoring both EGEI and QGEN until the merge, also keeping an eye at Qiagen's earning's report in May.

Not sure if I'll take the risk of buying QGEN shares before earnings, but I'll definitely watch to see what their report says.

Regardless, it seems that Qiagen is a good company to help promote eGene's products. If bird flu becomes a more widespread problem, it'll be great to see eGene's systems being used to help identify those infected.

Good luck to all.

[Horror_ Fn]

Because the price seems to be fixed around 1.30, it doesn't seem to be a threat to hold for awhile. I'm thinking it is a better deal right now to hold until the merge. It may spark a PPS hike in Egene too. That's what I would want.

I have had shares for a long time now and I was hoping to let my investment grow with the company. I may let it grow with Qiagen as well. They are doing well also.

I appreciate all your comments. For now, I've decided to hold until something makes me pull the trigger. No get rich scheme through these guys.

Two good companies, coming together...

[cojin]

Well, the 10-K came out before the closing bell today.

Sales up over 100% for the year. Net loss lower by over 8%. I noticed a large amount of money going into marketing, which won't be much of a problem in the future with Qiagen.

Of course, this report may not affect the stock price because of the Qiagen news. In my opinion, EGEI may go up significantly only if QGEN increases sharply after its earnings report in May. Otherwise, EGEI should only move a few cents, maybe up to $1.40 as long as QGEN doesn't go down much.

[quickpix]

It looks like a 1.30 is a good sell price after re looking at things. The buy out price is a little higher but not much. To bad if they would not have sold out we were looking at a 10 dollar stock in no more than a year maybe.

[Horror_ Fn]

A raise in one or both companies' PPS is exactly what I'm hoping for at this time. Preferably Egene's, for tax purposes.

I've always believed in Egene and now is the time where show me their value. They recently signed with most of China, which was HUGE!

Strong Buy!

[cojin]

I'm confused as well.

The press release says that for each EGEI share, we get $0.65 plus 0.0416 shares of QGEN.

Supposedly, the number of outstanding EGEI shares is 18.21 million. Also, the press release says that, based on the average price of QGEN in the past 20 days, the deal would be about $34 million. However, if I use the 18.21M number and $18 for a QGEN share (which is on the high side), I get the following:

18,210,000 x (0.65 + (0.0416 x 18.00)) = 25,472,148.

So instead of $34M, I get about $25.5M. Did I calculate something incorrectly? Do I have the number of outstanding shares wrong? Or is there other cash (such as for debt) being paid in the deal?

At any rate, the price at the merger time will depend on QGEN's price. Currently at $18, that's about .65 + .75, or $1.40.

QGEN will announce earnings soon (early May?), so hopefully it will have good news that raises the QGEN price, subsequently increasing the future EGEI price.

We may also learn more from eGene's annual report (10-K) which should be released soon.

Good luck.

[Horror_ Fn]

I'm a little confused as to what I should do exactly. I dunno if I should hold all my shares or sell in the near future.

I looked at the proposition and it appears we will get .65 a share and an issuance of the new compnaies shares to boot. Breaking the numbers down this weekedn.

Any comments or advice? I haven't owned a stock that has been bought out before.

[quickpix]

money to be made here big time here. 34 Million dollar buyout should bring at least 3.00 a share.

http://today.reuters.com/news/articleinvesting.aspx?view=CN&WTmodLOC=C3-News-2&symbol=QGEN.O...

[Horror_ Fn]

I'm holding long and look forward to what this compnay can do in 2007 thru 2009.

STRONG BUY!

[jcryan19]

With the last quarter being profitable, I think the coming one will be a knock out.

Jim

[Horror_ Fn]

An great read done last year about the direction of this company. Billions...

http://www.genengnews.com/articles/chitem.aspx?aid=1620

Go long!

[Horror_ Fn]

It's official on this date!

EGENE is rated a BUY!

http://www.americanbulls.com/StockPage.asp?CompanyTicker=EGEI&MarketTicker=OTC&TYP=S

[Horror_ Fn]

Plenty of good news coming out for these guys and I just saw that the Bird flu epidemic is getting bad in China.

Thank goodness for EGENE!

http://www.marketwatch.com/news/story/egene-receives-notice-allowance-us/story.aspx?guid=%7B664E93FD...


http://www.marketwatch.com/news/story/egene-gene-company-ltd-enter/story.aspx?guid=%7B2D80DCE9%2DDCE...

ALL GOOD SOON!

[Horror_ Fn]

It's harder to trade your shares in right now because of the volume also. I don't have a day trader account either. I am long.

This is fantastic news!

http://biz.yahoo.com/bw/070301/20070301005878.html?.v=1 with EGENE.

[jcryan19]

With April being the month for the Annual Report, I might try to make some money if it seems over heated.

There is often a 5 cent swing in a day, though I don't have a day trader account.


Jim

[Horror_ Fn]

Are you doing quick run up sells or are you for long?

I'm in long.

Either way, sounds like you're happy with our company so, great!

EGENE!!!

TJ

[jcryan19]

It's funny that more people are not here wanting to talk about it.

I'm making money on it so I guess that's the most important thing... LOL

Take care, Jim

[Horror_ Fn]

Here's a link from MSN showing some numbers and signs of growth. Look under financial highlights.

http://moneycentral.msn.com/detail/stock_quote?Symbol=egei

[Horror_ Fn]

EGENE IS A BUY over a BUCK!

Their income is higher every quarter by over 100% and will continue to grow. They will soon be able to charge more for their product as the need grows and that will increase their profit margin. They are continuing to sign more contracts and customer chains!

Bottom line:

GROWTH

and for the biotech sector, this is a rare occurrence.

Target 2.09

get in now or soon and that'll be just fine!

[Horror_ Fn]

We have a long way to go. Hopefully, the year will start to pick up.

The entire market has been abused for most of the year.

Time for it and EGENE to fight back!

TJ

[jcryan19]

Well things are going in the right direction.

Nice

Jim

[Horror_ Fn]

I don't mean just EGENE either.

This year has started out rough and the best is yet to come.

We must think about our options. Choose wisely.

Have a great day!

TJ

[Horror_ Fn]

We are always at the mercy of Wall St. It's kinda sad that someone else can have control of your securities.

One thing we always have is time...

It's time to buy!

[jcryan19]

Well we are getting our buts kicked today, interesting how all the trades seem to happen in the morning.

Jim

[Horror_ Fn]

This is a company that could rocket UP at any time.

Let's go with it Jim!

E GENE!!

[jcryan19]

Already did, was able to buy some at .73 and .74, what a steal.

Take care, Jim

[Horror_ Fn]

Buy NOW!

This is a huge dip that cannot be overlooked. Almost 50 cents lower than the weeks high!

NOW IS THE TIME!

[Horror_ Fn]

I have increased my holdings after witnessing the climb up!

This is one of the few Biotech stocks that isn't drowned in debt and they have international power already. Not to mention a valid product with many contracts. That's alot more than I can say for most Biotech companies.

There will be some more great news coming. Want a good biotech stock?

Get EGENE!

[audreyhepburn]

Locked and loaded! Waiting for the great news next week! GLTA!

[jcryan19]

OK people wake up, we are on the upswing.


Jim

[quickpix]

What skeletons are in the closet here? Bought some to hold but this looks to easy. These guys ex con's or what is the story?

[silverfox1155]

With this kinda volume the PPS is probably personal and not driven by logic. Someone could be getting out because they're tired of investor disinterest (low volume) in the stock and there are always buyers at the supports. At this level, I'm now looking at this very closely...trying to find out why such an exclusive and innovative invention is being ignored. I found your calls to the company a motivator in my interest too. Thanks.

[jcryan19]

It's true and the amazing thing is the drop in share price by 11 cents, it makes know sense to me.

Oh well that's the stock market.

Jim

[silverfox1155]

Do my eyes deceive me or does EGEI have their first net profit showing on the annual income statement.

[ProfitScout]

eGene Inc. and City of Hope's Dr. David Senitzer Presented 'The End of Agarose Gel Electrophoresis' at the 2006 Annual Meeting of the American Society for Histocompatibility and Immunogenetics in San Diego

IRVINE, Calif., Oct 25, 2006 (BUSINESS WIRE) -- Dr. David Senitzer, Ph.D., DABMLI, DABHI, Director of the Histocompatibility Laboratory at the City of Hope National Medical Center (Duarte, Calif.), presented his HLA genotyping work using the first automated HLA SSP genotyping system from eGene (OTCBB:EGEI) at the 32nd annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) at the Sheraton San Diego Hotel & Marina in San Diego, California, recently. Dr. Senitzer described the system as "The End of Agarose Gel Electrophoresis."

In his presentation (available on eGene's website, www.egeneinc.com), Dr. Senitzer noted that he wished to replace serology (blood testing to detect the presence of antibodies in the blood serum that may adversely affect bone marrow transplants) with an analytical tool that was more accurate and easier to perform. He said that current techniques -- polyacrylamide and agarose gel techniques -- did not match the cutting-edge technology available for genetic analysis. Citing the "ambiguous combinations resolved by PCR-SSP amplification," an alternative tissue typing technique to serology, Dr. Senitzer explained how eGene's automated multicapillary electrophoresis system provides high-resolution HLA (human leukocyte antigen) SSP typing results for 96 samples in 25 minutes, using a cartridge inserted directly into the system.

"The system is automated from setup to analysis, saving 30 to 40 percent in labor costs," Dr. Senitzer said. "There is no loading, pipetting, electrophoresing gel, taking pictures with an ultraviolet light, or annotating. The 96-well plate goes directly from PCR to the automated analyzer."

Further, Dr. Senitzer cited the advantage of using under 1 microliter of sample, enabling rerunning; the high resolution and ease of interpretation; and the ability to import the data into a patient database. He added that the eGene cartridge can be reused for 3,000 PCR sample analysis per cartridge.

Ming S. Liu, Ph.D., CEO of eGene, added, "There are nearly 600 HLA laboratories worldwide routinely checking the individual HLA genotype for organ and bone marrow transplantation. We believe our automatic, affordable, user-friendly genotyping system represents the future of HLA genotyping analysis."

About ASHI

ASHI (www.ashi-hla.org) is a not-for-profit association of clinical and research professionals including immunologists, geneticists, molecular biologists, transplant physicians and surgeons, pathologists and technologists. As a professional society involved in histocompatibility, immunogenetics and transplantation, ASHI is dedicated to advancing the science and application of histocompatibility and immunogenetics; providing a forum for the exchange of information; and advocating the highest standards of laboratory testing in the interest of optimal patient care.

ASHI is a member of the United Network for Organ Sharing and has liaisons with several other scientific and medical organizations including the College of American Pathologists, American Association of Blood Banks, American Association of Tissue Banks, American Society of Human Genetics, the National Marrow Donor Program, American Board of Transplant Coordinators, North American Transplant Coordinators Organization, American Society of Transplant Physicians, American Society of Transplant Surgeons, and the American Board of Histocompatibility and Immunogenetics.

About Dr. David Senitzer

Dr. Senitzer has been director of the Histocompatibility Laboratory at the City of Hope National Medical Center since 1994. Prior to that, he served as director of the Transplantation Immunology Laboratory and associate professor of surgery (immunology) at Montefiore Medical Center/Albert Einstein College of Medicine Bronx, New York and associate professor, department of microbiology, associate professor of pathology, and director of the Tissue Typing and Cellular Immunology Laboratory, Medical College of Ohio at Toledo (Toledo, Ohio).

About eGene Inc.

eGene Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.

eGene's HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The Company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.

SOURCE: eGene Inc.



CONTACT: Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
[e-mail]
or
Schneider the Writer for eGene Inc.
Ilene Schneider, 949-786-6270
[e-mail]


Copyright Business Wire 2006

-0-

KEYWORD: United States
North America
California
INDUSTRY KEYWORD: Health
Biotechnology
Genetics
Medical Devices
Research & Science

[ProfitScout]

eGene Inc. Will Introduce the First Automated HLA SSP Genotyping System at the 2006 Annual Meeting of the American Society for Histocompatibility and Immunogenetics in San Diego, California, October 16-20, 2006

IRVINE, Calif., Oct 11, 2006 (BUSINESS WIRE) -- eGene Inc. (OTCBB:EGEI), developer of a revolutionary high-performance genetic analysis technology, today announced that it will introduce the first automated HLA SSP genotyping system at the 32nd annual meeting of The American Society for Histocompatibility and Immunogenetics (ASHI) at the Sheraton San Diego Hotel & Marina in San Diego, California, on October 16-20, 2006.

Ming S. Liu, CEO of eGene, made the announcement noting: "eGene's HLA SSP digital genotyping technology will benefit HLA (human leukocyte antigen) genotyping analysis by not only replacing labor-intensive slab gel electrophoresis methods but also simplifying and digitalizing the tedious data process work. eGene will attend this meeting to introduce our products to HLA laboratories. We will host a customer presentation and live system demonstrations during this meeting, so people can experience first-hand our automated genotyping technology. Our automated HDA-GT12 genetic analyzer has already been used by HLA lab in the City of Hope Hospital National Medical Center for more than 30,000 tests per month. There are nearly 600 HLA laboratories worldwide routinely checking the individual HLA genotype for organ and bone marrow transplantation. We believe our automatic, affordable, user-friendly genotyping system represents the future of HLA genotyping analysis."

eGene's Booth Number is 512.

About ASHI

ASHI (www.ashi-hla.org) is a not-for-profit association of clinical and research professionals including immunologists, geneticists, molecular biologists, transplant physicians and surgeons, pathologists and technologists. As a professional society involved in histocompatibility, immunogenetics and transplantation, ASHI is dedicated to advancing the science and application of histocompatibility and immunogenetics; providing a forum for the exchange of information; and advocating the highest standards of laboratory testing in the interest of optimal patient care.

ASHI is a member of the United Network for Organ Sharing and has liaisons with several other scientific and medical organizations including the College of American Pathologists, American Association of Blood Banks, American Association of Tissue Banks, American Society of Human Genetics, the National Marrow Donor Program, American Board of Transplant Coordinators, North American Transplant Coordinators Organization, American Society of Transplant Physicians, American Society of Transplant Surgeons, and the American Board of Histocompatibility and Immunogenetics.

About eGene Inc.

eGene Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.

eGene's HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The Company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.

SOURCE: eGene Inc.



CONTACT: Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
[e-mail]


Copyright Business Wire 2006

-0-

KEYWORD: United States
North America
California
INDUSTRY KEYWORD: Health
Genetics
Medical Devices
Research & Science
Other Health

[ProfitScout]

eGene Completes Successful Study of Rapid and Inexpensive Detection of H5N1 Avian Flu Strain with Primers from Genome Institute of Singapore

IRVINE, Calif., Sep 25, 2006 (BUSINESS WIRE) -- eGene, Inc. ( EGEI ), a leading bioengineering company and developer of a compact and automated digital genetic analyzer, today announced that it had recently, using H5N1 avian influenza primers provided by the Genome Institute of Singapore, completed a successful application study that demonstrated that eGene's HDA-GT12 Genetic Analyzer can successfully detect H5N1 avian influenza to as few as 10 viral RNA copies.

The purpose of the study was to analyze the viability of developing a rapid, highly sensitive and low cost mass screening approach to detect the H5N1 influenza (bird flu) virus using a single step RT-PCR and automated HDA-GT12(TM) system.

The resulting report indicated that the HDA system, in combination with the Institute's single step RT-PCR assay, is a simple and sensitive assay for H5N1 avian influenza detection that can detect as few as 10 copies of the viral RNA. Furthermore, the sample analysis rate in the HDA system is approximately two samples per minute, so a total of 96 samples in a 96-well plate can be analyzed in 50 minutes. The calculated test cost of HDA-GT12 system is less than a dollar per sample (US), making it ideal for mass screening. The eGene system can also be used as a portable H5N1 avian influenza detection tool in field operations, since collected digital data and analyzed results can be stored and transferred in electronic format.

"The spread of avian influenza is still a major concern in the world," said Dr. Ming S. Liu, chief executive officer of eGene. "Continuous outbreaks of this highly pathogenic strain could unleash a pandemic that would have the potential to be as deadly to the population as the epidemic strain of influenza was in 1918. A fast, sensitive and low cost analysis to identify the contamination of the viral RNA in the poultry market can be one of the key factors to prevent the mass spread of the virus. We are pleased that eGene has been able to use the Genome Institute's H5N1 primers to develop a powerful and effective tool that may be applicable for bird flu screening."

eGene developed the HDA-GT12(TM) (high-performance DNA analyzer for genotyping on 12 channels), currently in use at more than 100 hospitals and research centers worldwide. The system analyzes the genetic fingerprints of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions, and ensures the quality of fragmented cRNA. The Company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.

About Genome Institute of Singapore

The Genome Institute of Singapore (GIS) is a member of the Agency for Science, Technology and Research (A*STAR). A national initiative established in 2001, the research institute's mission is to be a world-class genomics institute and a centre for genomic discovery. GIS pursues the integration of technology, genetics and biology towards the goal of individualized medicine. The genomics infrastructure at GIS is utilized to train new scientific talent, to act as a bridge between academic and industrial research, and explore scientific questions of high impact. For its H5N1 avian influenza virus research, GIS has developed a set of proprietary PCR primers which have been used successfully worldwide (Brunei, Oman, Kuwait, UK, UAE, France, Vietnam and Indonesia). In 2005, the World Health Organization (WHO) Influenza Centre has tested the primers and found it to be highly specific and sensitive.

About eGene, Inc.

eGene, Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.

SOURCE: eGene, Inc.

Martin E. Janis & Company, Inc. for eGene, Inc.
Beverly Jedynak, 312-943-1100, ext. 12
[e-mail]


Copyright Business Wire 2006

[ProfitScout]

Forensic Laboratories at Bureau of Investigation Ministry of Justice, Taiwan Use eGene's HDA-GT12(TM) System for DNA Identification Work

IRVINE, Calif., Aug 29, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developer of a revolutionary high-performance genetic analysis technology, announced today that the Bureau of Investigation Ministry of Justice, Taiwan has purchased an eGene HDA-GT12(TM) System for DNA identification work.

"We use this device to speed up the checking of PCR amplified products before mitochondrial DNA sequencing. We also use this system to detect the polymorphism in behavior-gene related study," said Mr. Chang-En Pu, section chief of the forensic laboratory. "We have saved time and material costs compared to using agarose-gel electrophoresis."

Ming S. Liu, CEO of eGene, noted: "DNA technology has been widely used in forensic identification to provide evidence in each case. We are excited to see forensic labs start to use our HDA system in their DNA analysis work. I think our compact, automated high throughput digital genetic analyzer can provide many benefits to the forensic DNA activities because of its low cost and high performance."

The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes the genetic fingerprints of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. eGene sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.

About Bureau of Investigation Ministry of Justice (MJIB), Taiwan

MJIB, Taiwan is a governmental, judicial, investigation agency that is responsible for safeguarding national security, maintaining social stability and protecting the people's well-being. This bureau is responsible for the investigation of violations against national security and interests, and matters concerning internal security.

About eGene Inc.

eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to publicly release any revision, which may be made to reflect events or circumstances after the date hereof.

SOURCE: eGene Inc.

Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
[e-mail]


Copyright Business Wire 2006

[audreyhepburn]

Well I liked today's move...now it can double!

[manny t]

EGEI,

eGene's HDA-GT12(TM) System Used by City of Hope National Medical Center for Automated HLA Genotyping for Genetic Matching of Bone Marrow
Monday August 7, 2:30 pm ET


IRVINE, Calif.--(BUSINESS WIRE)--Aug. 7, 2006--eGene Inc. (OTCBB:EGEI - News), developer of a revolutionary high-performance genetic analysis technology, announced today that HLA Laboratory in City of Hope National Medical Center (City of Hope, Calif.) has used eGene's HDA-GT12(TM) System for automated HLA genotyping for matching of bone marrow transplants.
ADVERTISEMENT


"We are using eGene's automated HDA-GT12(TM) genetic analyzer that replaces our current manual agarose gel electrophoresis process for high-resolution HLA SSP (sequence specific primer) genotyping," said Dr. David Senitzer, the director of the HLA Laboratory. "This highly sensitive system only consumes less than one microliter of DNA samples for each analysis and drastically reduces biohazardous waste. It eliminates tedious manual pipetting process of thousands of DNA samples into agarose gels in our daily routine work and provides high-quality images of digital data from sample handling to data management. eGene provides a great opportunity to increase the use of automation for high-resolution HLA genotyping, which has been our goal for the future of HLA genotyping."

Ming S. Liu, CEO of eGene, noted: "HLA genotyping is urgently needed for cancer treatment since it provides bone marrow matching information. It is exciting to provide HLA genotyping application with our HDA-GT12(TM) System. I think our compact, automated high throughput digital genetic analyzer can transform the current manual HLA genotyping process using traditional gel electrophoresis into an automatic new era."

"I believe our HDA system could be adopted easily in many laboratories doing HLA genotyping work," he continued. "We have also seen increased demand for genotyping work in the field of molecular diagnostics, and more users are integrating our HDA-GT12 system in their routine genotyping analysis," Dr. Liu said.

The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes the genetic fingerprints of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.

[ProfitScout]

eGene Provides Progress Report on Bird Flu Analysis; Company Describes its System to Reporters at AACC Meeting in Chicago

IRVINE, Calif., Jul 27, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), a leading bioengineering company that has done for DNA analyzers what the desktop did for computers, through its development of a desktop rapid DNA analyzer, today described its progress on potential use in screening bird flu and its automated HLA-SSP genotyping system for news reporters at a meeting of the American Association for Clinical Chemistry (AACC) meeting in Chicago.

Dr. Ming Liu, chief executive officer of eGene, described the company's analyzer at a press conference "Disease analysis using DNA." In the conference, Liu discussed how eGene's system can screen for genetic matching of bone marrow, as well as the system's use in avian flu and other diseases.

In particular, Liu noted that the company has made great progress in its work on bird flu H5N1 strain detection. "Currently our system can successfully detect as low as 1,000 copies of bird flu viral load. We are developing a simple, fast, highly specific and sensitive bird flu virus detection product with an affordable detection cost for massive screening. The detection cost per test is expected to be a major issue in the prevention of the spread of bird flu. Bird flu detection should be affordable to the massive screening in the countries where there is a real need to halt its spread," said Liu. "Furthermore, recent reports have indicated that the bird flu viral strain may have many new mutations. The speed of research for the development of a bird flu detection kit needed to catch the new mutations becomes very important to help halt the spread of this illness. Our bird flu detection method can allow researchers to develop the new methods to detect new mutations easily and fast."

As a result of this, Liu believes that the company has a clear direction in the bird flu detection area. "We plan to provide fast and affordable bird flu detection and work with the researchers in these countries who are working on means to quickly identify rapid mutations of any possible new strain."

The HDA-GT12(TM) (high-performance DNA analyzer for genotyping on 12 channels) is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage. eGene recently announced that it can successfully identify the DNA of the bird flu virus in as little as five minutes for 12 samples or 50 minutes for 96 samples.

AACC is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists, and other individuals involved with clinical chemistry and clinical laboratory science disciplines. Founded in 1948, the society has 9,500 members and is headquartered in Washington.

eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity, while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.

SOURCE: eGene Inc.

Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
[e-mail]


Copyright Business Wire 2006

[manny t]

Use of eGene's DNA Analyzer as Described by GenVault in Genetic Engineering News
Thursday July 20, 12:00 pm ET
Fast, Cost-Effective and Automated Sample-Handling Analysis


IRVINE, Calif.--(BUSINESS WIRE)--July 20, 2006--eGene Inc. (OTCBB:EGEI - News), a leading biotechnology company that has developed a compact and automated digital genetic analyzer, again appears in the prestigious "Genetic Engineering News'" July 1, 2006 (Vol. 26, No. 13) issue, in the story: "OMICS: Barcoding and Automated Electrophoresis."
ADVERTISEMENT


In the article, which is a tutorial that describes how eGene client, GenVault is using the system for oligonucleotide quality control work in its DNA storage business, authors James C. Davis, Ph.D., David T. Wong and Jennifer McEvoy described how in the past they used gel electrophoresis to check the quality of incoming oligos and the GenCodes. "Using traditional electrophoresis methods, this process can be cumbersome and time consuming, depending on the number of samples that need to be processed," they wrote. The authors noted that in a high-through-put laboratory efficient use of time is essential in keeping production costs reasonable.

According to the authors, they recently switched to eGene's HDA-GT12 system, which "has allowed for fast, cost-effective and automated sample-handling analysis." The full article is available at http://www.genengnews.com/current/article.aspx?cat=Tutorial&id=1769.

The HDA-GT12(TM) (high-performance DNA analyzer for genotyping on 12 channels) is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage. eGene recently announced that it can successfully identify the DNA of the bird flu virus in as little as five minutes for 12 samples or 50 minutes for 96 samples.

eGene Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.



Contact:
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
[e-mail]

--------------------------------------------------------------------------------
Source: eGene Inc.

[ProfitScout]

eGene's Cost Benefits Outlined in Application Note in June/July Issue of American Laboratory News Magazine
7/18/2006 11:58:05 AM

IRVINE, Calif., Jul 18, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), a leading bioengineering company that has developed a compact and automated digital genetic analyzer, is the focus of an Application Note article in the June/July 2006 issue of American Laboratory News. In the article, the cost benefits of the Multicapillary Electrophoresis System developed by eGene are compared to traditional methods of genetic analysis.

As the article states: "the HDA-GT12 system reduces separation time from two or three hours to 10 minutes. It eliminates the labor-intensive procedures of manual sample loading, visual examination, data analysis, photo-taking and record-keeping. The system enables minimal human intervention, thus reducing the possibilities of human error." The article provides specific cost comparisons of the eGene system versus conventional gel electrophoresis of 12 samples. The total difference: with the traditional methods used, the cost was anywhere from $37.48-$67.48 for 12 samples whereas the eGene costs were significantly reduced to only $6.40 for the same 12 samples.

Equally impressive were the exact comparisons of the workflow time comparisons. Conventional agarose gel electrophoresis of 12 samples took a total of 101-191 minutes versus eGene's fast 10.2-minute effort.

"The benefits are unmistakable," said Dr. Ming Liu, chief executive officer of eGene. "When we demonstrate our system to lab workers, researchers and other scientists, they immediately see the benefits of our system."

American Laboratory News is edited for chemists and life scientists who have a professional interest in the application of modern scientific instrumentation for the practical use in laboratories. The editorial content covers the latest advances in laboratory instrumentation.

The HDA-GT12(TM) (high-performance DNA analyzer for genotyping on 12 channels) is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage. eGene recently announced that it can successfully identify the DNA of the bird flu virus in as little as five minutes for 12 samples or 50 minutes for 96 samples.

eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.

SOURCE: eGene Inc.

Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
[e-mail]


Copyright Business Wire 2006

[silverfox1155]

The exhibit starts today....news should be forthcoming. Could give it a much needed kick.

[silverfox1155]

AACC (American Association for Clinical Chemistry) is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry and other clinical laboratory science-related disciplines.